top of page
AB-Life-Global-logo
Original illustration of amber skincare bottles and professional retinol sourcing

Retinol Sourcing in 2026: EU Vitamin A Rules and a GCC Buyer’s Checklist for Korean Skincare

JUSTIN PARK
Nov 15
7 min read

Retinol remains one of the most discussed ingredients in global skincare, but sourcing a vitamin A-based cosmetic requires more than choosing a high percentage on an attractive bottle. For buyers evaluating Korean skincare for the Gulf, ingredient identity, formulation quality, labeling, safety evidence and the rules of each target country all deserve careful attention. In 2026, the European Union’s updated vitamin A provisions offer a useful case study in why transparent technical files matter.

This article is for distributors, clinic retail purchasers and professional sourcing teams. It explains which ingredients are covered by the relevant EU rule, how to read retinol equivalent (RE) limits, why stability needs finished-product evidence, and what the Saudi Food and Drug Authority’s cosmetic notification process says about market entry. European restrictions are not automatically UAE or GCC-wide laws; local compliance must always be checked separately.

Understand the retinoid family before comparing percentages

Retinoids are vitamin A-related molecules, but the name is not one specification. Retinol, retinyl acetate and retinyl palmitate are chemically distinct ingredients. A label that says “retinol complex 1%” may describe a raw-material premix rather than the concentration of active retinol in the finished formula. Buyers should obtain the exact INCI ingredient names, final concentrations and a clear explanation of how the manufacturer describes each active.

Retinaldehyde, hydroxypinacolone retinoate and retinoic acid also belong to a broader discussion about retinoids, but each needs its own technical and regulatory assessment. The EU measure described here specifically addresses three named vitamin A ingredients in its relevant restriction entry. It is misleading to report that all retinoids are banned or governed by an identical numerical ceiling. Classification also depends on intended use and marketing claims, not packaging appearance alone.

The EU rule: two limits, three named ingredients

Commission Regulation (EU) 2024/996 amended the EU Cosmetics Regulation. For retinol, retinyl acetate and retinyl palmitate, the relevant Annex III entry sets maximum use levels expressed as retinol equivalents (RE): 0.05% RE for body lotion and 0.3% RE for other leave-on and rinse-off cosmetics. These thresholds refer to the named ingredients and category-specific conditions in the EU law, not every vitamin A-like ingredient on the market.

For the specified ingredients, the EU also requires the wording “Contains Vitamin A. Consider your daily intake before use.” The restriction applies to newly placing non-compliant products on the EU market from 1 November 2025; such products may not be made available on that market from 1 May 2027. The two milestones refer to different market activities. Neither date is a GCC import deadline, and neither automatically resolves a product’s status under Saudi or UAE requirements.

Retinol equivalent is not the same as a marketing percentage

Commercial retinoid ingredients can arrive in oils or delivery systems with different active contents. Therefore, a declared percentage of a premix should not be treated as the percentage of retinol in a final cosmetic. A credible dossier separates the raw material’s composition, actual finished-product concentration and the relevant retinol-equivalent calculation where applicable. Buyers should ask for a calculation note, exact INCI names, batch specifications and the appropriate certificate of analysis.

The European Commission’s Scientific Committee on Consumer Safety revised its scientific vitamin A opinion in 2022. It discussed consumer safety at specified RE levels and possible additional exposure through cosmetics. That opinion informed EU risk management but is not itself a product-specific authorization or a substitute for testing a marketed formula. Assess the actual SKU rather than assuming that an ingredient safety opinion, or a European label design, verifies every performance or market-entry claim.

EU 2024/996 concentration comparison. 0.05% RE: body lotion. 0.3% RE: other leave-on and rinse-off cosmetics. Not a GCC-wide limit.

EU 2024/996 concentration comparison. 0.05% RE: body lotion. 0.3% RE: other leave-on and rinse-off cosmetics. Not a GCC-wide limit.

Two EU milestones that procurement teams should track

When a Korean supplier sells into Europe as well as the Gulf, its portfolio may include products formulated for different markets or older stock. Importers should distinguish the legal act of placing a product on the EU market from the subsequent act of making it available. The November 2025 and May 2027 EU milestones concern non-compliant products containing the specified vitamin A derivatives under the regulation.

Those dates do not establish whether a Saudi-listed product or an intended UAE launch is eligible for sale. Review the target country, SKU, formula, version of the label and distribution record separately. A multi-market product matrix reduces the risk of copying an EU warning onto a Gulf label without checking local requirements or advertising an EU-compliant formulation as universally approved.

EU transition dates: 1 November 2025 for new placing on the market; 1 May 2027 for making non-compliant products available on that market.

EU transition dates: 1 November 2025 for new placing on the market; 1 May 2027 for making non-compliant products available on that market.

Stability is a formulation-specific question

Many retinoid compounds are sensitive to light, oxygen and heat, but the speed and magnitude of degradation depend on the particular formula and packaging. A peer-reviewed study of commercial cosmetics examined 12 products over long-term, accelerated and photostability conditions and observed considerable variability. Its findings support careful testing; they should not be used to claim that every retinol product degrades equally or that a single packaging format always protects every formulation.

Supplier due diligence should include stability data for the actual finished formula in the proposed container, a justified shelf life, test methods and acceptance criteria. When relevant, ask whether the assay monitors retinoid content rather than appearance alone. Airless pumps, opaque bottles and encapsulation may be useful formulation choices, but none is a standalone guarantee. Review practical storage and transport assumptions for Gulf distribution without inventing an unverified safe temperature range.

A four-gate checklist for Korean skincare buyers

Gate 1 — Formula: Obtain the complete INCI list, exact vitamin A derivative, product version, final active content and specifications. Check whether the stated marketing percentage is a premix concentration. Document controls for any formula, supplier or package changes.

Gate 2 — Evidence: Match claims to appropriate evidence for the finished product or clearly identify when a claim rests only on general ingredient research. Request the applicable testing plan and substantiation. An ingredient mechanism, a clinical study of a different formula and the actual product claim are different types of evidence.

Gate 3 — Stability: Verify the shelf-life rationale, real-time and accelerated studies where appropriate, final container compatibility, label storage instructions and relevant logistics assumptions. Match laboratory reports to the exact SKU and packaging proposed for distribution.

Gate 4 — Market: Have a qualified local specialist check cosmetic classification, permitted ingredients, labeling languages, warnings, product notification, importer obligations and advertising rules for each country. Separate Saudi, UAE and other market files instead of treating the GCC as one unified authorization process.

Four evidence gates: formula identity, claims substantiation, finished-product stability and destination-market compliance.

Four evidence gates: formula identity, claims substantiation, finished-product stability and destination-market compliance.

Saudi Arabia: notification is not a marketing endorsement

SFDA’s official guidance on cosmetic product notification describes the GHAD electronic system. Under the current guidance, cosmetic products are to be listed before import or trade, and the notifier is responsible for the accuracy of ingredient information, product labels and supporting records. The authority asks for artwork and ingredient concentrations and explains that therapeutic-style claims can affect classification. These are concrete purchasing questions, not administrative details to leave until after a commercial agreement.

The same guidance states that a marketing notification should not be used as proof of SFDA clinical evaluation or approval of the product. An EU-compliant carton, a certificate held by a factory or a broad quality-management claim cannot replace the current local pathway. Requirements can evolve, so consult the latest SFDA texts and an authorized local regulatory professional for each proposed product.

Consumer education and responsible claims are part of B2B quality

Distributors and clinic retail teams also inherit responsibility for the accuracy of retail-facing education. The American Academy of Dermatology cautions that retinoids may irritate skin and advises against use during pregnancy. Consumer copy should therefore avoid promising a universally irritation-free experience or converting a cosmetic skin-appearance statement into a disease-treatment claim. Product-specific instructions and professional medical advice remain important.

Resist unsupported phrases such as “zero side effects,” “clinically proven on all skin types,” “EU approved across the GCC” or “strongest concentration equals best results.” Reliable marketing can be commercially persuasive without implying a level of evidence that was never supplied. If a manufacturer provides only ingredient-level research, describe it as such and avoid suggesting that the finished branded product reproduced the same outcome.

AB LIFE GLOBAL: a documentation-first partner conversation

AB LIFE GLOBAL connects Korean skincare and medical-aesthetic categories with international professional buyers and partners. For a potential GCC skincare distribution conversation, a productive starting point is the product category, intended consumer, manufacturer documentation, formula details, target market and evidence available for proposed claims. Different products can require very different pathways even when presented together in a beauty portfolio.

The discussion should not assume that any specific AB LIFE GLOBAL item contains retinol or already has a particular country authorization unless official product documentation verifies it. Likewise, professional injectables or energy-based devices should not be positioned as ordinary retail retinol substitutes. Our role is to support informed product selection and commercially realistic sourcing conversations, with independent regulatory checks where required.

Key takeaways and next steps

Before placing a purchase order, verify the actual retinoid molecule, distinguish premix percentages from active concentration, consider EU 2024/996 only within its legal scope, review stability of the finished product, and confirm destination-market classification and notification. A complete technical file and responsible claims may matter more to long-term distribution than a dramatic percentage headline.

For a professional discussion about Korean skincare sourcing, supplier documentation and possible Gulf distribution opportunities, visit www.ablife-global.com or contact dypark@ablife-global.com. Product selection, labeling, availability and market-entry decisions remain subject to verification for the exact product and intended jurisdiction.

Primary sources and further reading

 
 
 

Comments


Commenting on this post isn't available anymore. Contact the site owner for more info.
bottom of page